Imidazoline scaffold in medicinal chemistry: a patent review (2012–2015)

References

• Dardonville C, Rozas I, Alkorta I. Similarity studies on guanidinium, imidazolinium, and imidazolium cations: toward new bradykinin antagonists. J Mol Graph Model. 1998;16:150–156.
   PubMed Web of Science ®Google Scholar
• Guan X, Hu Y. Imidazoline derivatives: a patent review (2006 – present). Expert Opin Ther Patents. 2012;22:1353–1365.
   PubMed Web of Science ®Google Scholar
• Krasavin M. Biologically active compounds based on the privileged 2-imidazoline scaffold: the world beyond adrenergic/imidazoline receptor. Eur J Med Chem. 2015;97:525–537.
   PubMed Web of Science ®Google Scholar
• Remko M, Walsh OA, Richards WG. Theoretical study of molecular structure, tautomerism, and geometrical isomerism of moxonidine: two-layered ONIOM calculations. J Phys Chem A. 2001;105:6926–6931.
   Web of Science ®Google Scholar
• Remko M, Van Duijnen PT, Swart M. Theoretical study of molecular structure, tautomerism, and geometrical isomerism of N-methyl- and N-phenyl-substituted cyclic imidazolines, oxazolines and thiazolines. Struct Chem. 2003;14:271–278.
   Web of Science ®Google Scholar
• Nanubolu JB, Sridhar B, Ravikumar K. Understanding the amino ↔ imino tautomeric preferences in (imidazole)imidazolidine-N-aryl(alkyl) systems: a case study of moxonidine drug and insight from the Cambridge structural database (CSD). Cryst Eng Comm. 2014;16:10602–10617.
   Web of Science ®Google Scholar
• Remko M, Swart M, Bickelhaupt FM. Theoretical study of structure, pKa, lipophilicity, solubility, absorption, and polar surface area of some centrally acting antihypertensives. Bioorg Med Chem. 2006;14:1715–1728.
   PubMed Web of Science ®Google Scholar
• Giovannitti JA Jr, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog. 2015;62:31–38.
   PubMedGoogle Scholar
• Orion Corporation. New alpha2 adrenoceptor agonists. WO2013150173.
   Google Scholar
• Kelly B, McMullan M, Muguruza C, et al. α2-Adrenoceptor antagonists: synthesis, pharmacological evaluation, and molecular modeling investigation of pyridinoguanidine, pyridino-2-aminoimidazoline and their derivatives. J Med Chem. 2015;58:963–977.
   PubMed Web of Science ®Google Scholar
• Del Bello F, Diamanti E, Giannella M, et al. Low doses of allyphenyline and cyclomethyline, effective against morphine dependence, elicit an antidepressant-like effect. ACS Med Chem Lett. 2012;3:535–539.
   PubMed Web of Science ®Google Scholar
• Del Bello F, Diamanti E, Giannella M, et al. Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity. ACS Med Chem Lett. 2013;4:875–879.
   PubMed Web of Science ®Google Scholar
• Allergan Inc. Method of activating regulatory T cells with alpha-2B adrenergic receptor agonists. US20120041031.
   Google Scholar
• Price RL. Treatment of autistic spectrum disorder. US20140309271.
   Google Scholar
• Lang R, O’Reilly M, Healy O, et al. Sensory integration therapy for autism spectrum disorders: a systematic review. Res Autism Spectr Disord. 2012;6:1004–1018.
   Web of Science ®Google Scholar
• Mazurov A, Hauser T, Miller CH. Selective α7 nicotinic acetylcholine receptor ligands. Curr Med Chem. 2006;13:1567–1584.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Company. Quinuclidine, 1-azabicyclo[2.2.1]heptane, 1-azabicyclo[3.2.1]octane, and 1-azabicyclo[3.2.2]nonane compounds as alpha-7 nicotinic acetylcholine receptor ligands. WO2013177024.
   Google Scholar
• Wu J, Zhang Y, Maida LE, et al. Scaffold ranking and positional scanning utilized in the discovery of nAChR-selective compounds suitable for optimization studies. J Med Chem. 2013;56:10103–10117.
   PubMed Web of Science ®Google Scholar
• Mazanetz MP, Laughton CA, Fischer PM. Investigation of the flexibility of protein kinases implicated in the pathology of Alzheimer’s disease. Molecules. 2014;19:9134–9159.
   PubMed Web of Science ®Google Scholar
• Gautam AK. A concise review on cyclin dependent kinase 5 (CDK5) inhibitors. J Integr Sci Technol. 2014;2:9–12.
   Google Scholar
• Eldar-Finkelman H, Martinez A. GSK-3 inhibitors: preclinical and clinical focus on CNS. Front Mol Neurosci. 2011;4:1–18.
   PubMed Web of Science ®Google Scholar
• Noscira SA. The University of Queensland. Therapeutic use of indole-dihydro-imidazole derivatives. WO2013167635.
   Google Scholar
• Glicksman MA, Cuny GD, Liu M, et al. New approaches to the discovery of cdk5 inhibitors. Curr Alzheimer Res. 2007;4:547–549.
   PubMed Web of Science ®Google Scholar
• Kramer T, Schmidt B, Lo Monte F. Small-molecule inhibitors of GSK-3: structural insights and their application to Alzheimer’s disease models. Int J Alzheimers Dis. 2012. doi:10.1155/2012/381029.
   PubMedGoogle Scholar
• Bharti N, Dontukurthy S, Bala I, et al. Postoperative analgesic effect of intravenous (i.v.) clonidine compared with clonidine administration in wound infiltration for open cholecystectomy. Br J of Anaesth. 2013;22:1–6.
   Google Scholar
• Allergan Inc. Methods of treating alpha adrenergic mediated conditions. US20120165380.
   Google Scholar
• Allergan Inc. Alpha-2B receptor agonist and anticonvulsant compositions for treating chronic pain. WO2013074320.
   Google Scholar
• Szacoń E, Rządkowska M, Kaczor AA, et al. Synthesis, central nervous system activity and structure-activity relationships of novel 1-(1-alkyl-4-aryl-4,5-dihydro-1H-imidazo)-3-substituted urea derivatives. Molecules. 2015;20:3821–3840.
   PubMed Web of Science ®Google Scholar
• Bektas N, Nemutlu D, Arslan R. The imidazoline receptors and ligands in pain modulation. Indian J Pharmacol. 2015;47:472–478.
   PubMed Web of Science ®Google Scholar
• Ferrari F, Fiorentino S, Mennuni L, et al. Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain. J Pain Res. 2011;4:111–125.
   PubMedGoogle Scholar
• Li JX, Thorn DA, Qiu Y, et al. Antihyperalgesic effects of imidazoline I2 receptor ligands in rat models of inflammatory and neuropathic pain. Br J Pharmacol. 2014;171:1580–1590.
   PubMed Web of Science ®Google Scholar
• Meregalli C, Ceresa C, Canta A, et al. CR4056, a new analgesic 12 ligand, is highly effective against bortezomib-induced painful neuropathy in rats. J Pain Res. 2012;5:151–167.
   PubMedGoogle Scholar
• Lanza M, Ferrari F, Menghetti I, et al. Modulation of imidazoline I2 binding sites by CR4056 relieves postoperative hyperalgesia in male and female rats. Br J Pharmacol. 2014;171:3693–3701.
   PubMed Web of Science ®Google Scholar
• Novartis AG. Pyrazine derivatives as ENaC blockers. WO2012035158.
   Google Scholar
• Novartis AG. Pyrazine derivatives as ENaC blockers. US20140113914.
   Google Scholar
• Novartis AG. Crystalline form of a succinate salt. WO2013140319.
   Google Scholar
• Sarnpitak P, Mujumdar P, Morisseau C, et al. Potent, orally available, selective COX-2 inhibitors based on 2-imidazoline core. Eur J Med Chem. 2014;84:160–172.
   PubMed Web of Science ®Google Scholar
• Qin J, Vinogradova O, Plow EF. Integrin bidirectional signaling: a molecular view. PLoS Biol. 2004;2:0726–7.
   Web of Science ®Google Scholar
• Perdih A, Sollner Dolenc M. Small molecule antagonists of integrin receptors. Curr Med Chem. 2010;17:2371–2392.
   PubMed Web of Science ®Google Scholar
• Penning TD, Russell MA, Chen BB, et al. Synthesis of cinnamic acids and related isosteres as potent and selective ανβ3 receptor antagonists. Bioorg Med Chem Lett. 2004;14:1471–1476.
   PubMed Web of Science ®Google Scholar
• Saint Louis University. Beta amino acid derivatives as integrin antagonists. WO2014015054.
   Google Scholar
• Ma D, Rajakumaraswamy N, Maze M. α2-Adrenoceptor agonists: shedding light on neuroprotection? Br Med Bull. 2005;71:77–92.
   PubMed Web of Science ®Google Scholar
• Sanders RD, Maze M. Alpha2-adrenoceptor agonists. Curr Opin Investig Drugs. 2007;8:25–33.
   PubMedGoogle Scholar
• Allergan Inc. N-(imidazolidin-2-ylidene)-heterocyclopenta[b]pyridine derivatives as modulators of alpha 2 adrenergic receptors. WO2013015984.
   Google Scholar
• Allergan Inc. Pharmaceutical compositions comprising 4-bromo-N-(imidazolidin-2-ylidene)-1H-benzimidazol-5-amine for treating retinal diseases. WO2013016252.
   Google Scholar
• Allergan Inc. Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect. US20130210876.
   Google Scholar
• Allergan Inc. N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors. WO2013016178.
   Google Scholar
• Imperial Innovations Limited. Medical University of Gdansk. Derivatives of 1-[(imidazolidin-2-yl)imino]indazole. WO2009071906.
   Google Scholar
• Sączewski F, Kornicka A, Rybczyńska A, et al. 1-[(Imidazolidin-2-yl)imino]indazole. Highly α2/I1 selective agonist: synthesis, X-ray structure, and biological activity. J Med Chem. 2008;51:3599–3608.
   PubMed Web of Science ®Google Scholar
• Wróblewska M, Kasprzyk J, Sączewski F, et al. Marsanidine and 7-Me-marsanidine, the new hypotensive imidazoline augment sodium and urine excretion in rats. Pharmacol Rep. 2013;65:1025–1032.
   PubMed Web of Science ®Google Scholar
• Boblewski K, Lehmann A, Sączewski F, et al. Vagotomy reveals the importance of the imidazoline receptors in the cardiovascular effects of marsanidine and 7-Me-marsanidine in rats. Pharmacol Rep. 2014;66:874–879.
   PubMed Web of Science ®Google Scholar
• Sączewski F, Kornicka A, Hudson AL, et al. 3-[(Imidazolidin-2-yl)imino]indazole ligands with selectivity for the α2-adrenoceptor compared to the imidazoline I1 receptor. Bioorg Med Chem. 2011;19:321–329.
   PubMed Web of Science ®Google Scholar
• Sączewski J, Hudson A, Scheinin M, et al. Synthesis and biological activities of 2-[(heteroaryl)methyl]imidazolines. Bioorg Med Chem. 2012;20:108–116.
   PubMed Web of Science ®Google Scholar
• Wasilewska A, Sączewski F, Hudson AL, et al. Fluorinated analogues of marsanidine, a highly α2-AR/imidazoline I1 binding site-selective hypotensive agent. Synthesis and biological activities. Eur J Med Chem. 2014;87:386–397.
   PubMed Web of Science ®Google Scholar
• UCL Business PLC. Treatment. WO2012020235.
   Google Scholar
• Imaki J, Mae Y, Shimizu S, et al. Therapeutic potential of alpha2 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders. Neurosci Lett. 2009;454:143–147.
   PubMed Web of Science ®Google Scholar
• Schann S, Greney H, Gasparik V, et al. Methylation of imidazoline related compounds leads to loss of α2-adrenoceptor affinity. Synthesis and biological evaluation of selective I1 imidazoline receptor ligands. Bioorg Med Chem. 2012;20:4710–4715.
   PubMed Web of Science ®Google Scholar
• Dardonville C, Rozas I. Imidazoline binding sites and their ligands: an overview of the different chemical structures. Med Res Rev. 2004;24:639–661.
   PubMed Web of Science ®Google Scholar
• Del Bello F, Bargelli V, Cifani C, et al. Antagonism/agonism modulation to build novel antihypertensives selectively triggering I1-imidazoline receptor activation. ACS Med Chem Lett. 2015;6:496–501.
   PubMed Web of Science ®Google Scholar
• Council of Scientific & Industrial Research. Shantani Proteome Analytics Pvt Ltd. Novel indazole compounds and a process for the preparation thereof. WO2015015519.
   Google Scholar
• Zhang Q, Zeng SX, Lu H. Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem. 2014;85:281–319.
   PubMedGoogle Scholar
• Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013;13:83–96.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Bernard D, Wang S. Small molecule inhibitors of MDM2-p53 and MDMX-p53 interactions as new cancer therapeutics. Biodiscovery. 2013;4:1–15.
   Google Scholar
• Hoffmann-La Roche Inc. Novel imidazolines as dual inhibitors of MDM2 and MDMX. US20140148443.
   Google Scholar
• St. Jude Children’s Research Hospital. Aryl-substituted imidazoles. WO2012045018.
   Google Scholar
• Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol. 2012;83:1021–1032.
   PubMed Web of Science ®Google Scholar
• Turner JG, Sullivan DM. RM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem. 2008;15:2648–2655.
   PubMed Web of Science ®Google Scholar
• El-Tanani M, Dakir EH, Raynor B, et al. Mechanism of nuclear export in cancer and resistance to chemotherapy. Cancers. 2016;8:1–11.
   Google Scholar
• H. Lee Moffitt Cancer Center & Research Institute Inc, University of Florida Research Foundation Inc. Novel drug targets to overcome de novo drug-resistance in multiple myeloma. WO2012075484.
   Google Scholar
• Rgenix Inc. Inhibitors of creatine transport and uses thereof. WO2015168465.
   Google Scholar
• OncoArendi Therapeutics Sp. z o.o. Derivatives of 1-(substituted sulfonyl)-2-aminoimidazoline as antitumor and antiproliferative agents. WO2014167446.
   Google Scholar
• Galderma Research & Development. Method for preventing or treating skin tumor. WO2012001065.
   Google Scholar
• Nikolic K, Veljkovic N, Gemovic B, et al. Imidazoline-1 receptor ligands as apoptotic agents: pharmacophore modeling and virtual docking study. Comb Chem High T SCR. 2013;16:1–22.
   PubMed Web of Science ®Google Scholar
• Ligon KL, Huillard E, Mehta S, et al. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron. 2007;53:503–517.
   PubMed Web of Science ®Google Scholar
• Mehta S, Huillard E, Kesari S, et al. The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell. 2011;19:359–371.
   PubMed Web of Science ®Google Scholar
• Tsigelny IF, Mukthavaram R, Kouznetsova VL, et al. Multiple spatially related pharmacophores define small molecule inhibitors og OLIG2 in glioblastoma. Oncotarget. 2015;1–15.
   PubMed Web of Science ®Google Scholar
• The Regents of the University of California. Novel therapeutics for brain cancer. WO2013188813.
   Google Scholar
• Bianco R, Melisi D, Ciardiello F, et al. Key cancer cell signal transduction pathway as therapeutic targets. Eur J Cancer. 2006;42:290–294.
   PubMed Web of Science ®Google Scholar
• Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:103–119.
   PubMed Web of Science ®Google Scholar
• De Luca A, Maiello MR, D′Alessio A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012;16(Suppl 2):S17–S27.
   PubMed Web of Science ®Google Scholar
• Pisces Therapeutics LLC. Malignant and non-malignant disease treatment with Ras antagonists. WO2013052765.
   Google Scholar
• University of Pittsburgh of the Commonwealth System of Higher Education. Compounds for treating HIV and methods for using the compounds. WO2014074628.
   Google Scholar
• Smithgall TE, Thomas G. Small molecule inhibitors of the HIV-1 virulence factor, Nef. Drug Discov Today Technol. 2013;10:e451–e548.
   PubMedGoogle Scholar
• Trible RP, Narute P, Emert-Sedlak LA, et al. Discovery of a diaminoquinoxaline benzenesulfonamide antagonist of HIV-1 Nef function using a yeast-based phenotypic screen. Retrovirology. 2013;10:1–17.
   PubMed Web of Science ®Google Scholar
• The Board of Trustees of the University of Illinois, the Regents of the University of California. Antibacterial compounds targeting isoprenoid biosynthesis. WO2014089226.
   Google Scholar
• Zhu W, Zhang Y, Sinko W, et al. Antibacterial drug leads targeting isoprenoid biosynthesis. Proc Nat Acad Sci. 2013;110:123–128.
   PubMed Web of Science ®Google Scholar
• Memorial Sloan-Kettering Cancer Center. Indole compounds and their use as antimicrobials. WO2014078294.
   Google Scholar
• Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. IDSA Rep Dev Pipeline. 2009;48:1–12.
   Google Scholar
• Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther. 2013;11:297–308.
   PubMed Web of Science ®Google Scholar
• University of South Florida, Torey Pines Institute for Molecular Studies. Bis-cyclic guanidine compound compositions, methods of use and treatment thereof. WO2015130547.
   Google Scholar
• Fleeman R, LaVoi TM, Santos RG, et al. Combinatorial libraries as a tool for the discovery of novel, broad-spectrum antibacterial agents targeting the ESKAPE pathogens. J Med Chem. 2015;58:3340–3355.
   PubMed Web of Science ®Google Scholar
• Reyes-Arellano A, Bucio-Cano A, Montenegro-Sustaita M, et al. Imidazolines as non-classical bioisosteres of N-acyl homoserine lactones and Quorum Sensing inhibitors. Int J Mol Sci. 2012;13:1284–1299.
   PubMed Web of Science ®Google Scholar
• Yitzhaki S, Rostron JE, Xu Y, et al. Similarities between exogenously- and endogenously-induced envelope stress: the effects of a new antibacterial molecule, TPI1609-10. PLoS One. 2012;7:e44896.
   PubMed Web of Science ®Google Scholar
• Barakat A, Al-Majid AM, Al-Qahatany FM, et al. Synthesis, characterization and antimicrobial activity of novel pharmacophores incorporating imidazoline-oxazoline scaffold. Bull Korean Chem Soc. 2014;35:562–568.
   Web of Science ®Google Scholar
• Demir B, Cerkez I, Worley SD, et al. N-halamine-modified antimicrobial polypropylene nonwoven fabrics for use against airborne bacteria. ACS Appl Mater Interfaces. 2015;7:1752–1757.
   PubMed Web of Science ®Google Scholar
• Rodriguez RA, Barrios Steed D, Kawamata Y, et al. Axinellamines as broad-spectrum antibacterial agents: scalable synthesis and biology. J Am Chem Soc. 2014;136:15403–15413.
   PubMed Web of Science ®Google Scholar
• Fuse S, Koinuma H, Kimbara A, et al. Total synthesis and stereochemistry revision of mannopeptimycin aglycone. J Am Chem Soc. 2014;136:12011–12017.
   PubMed Web of Science ®Google Scholar
• Ríos Martínez CH, Lagartera L, Trujillo C, et al. Bisimidazoline arylamides binding to the DNA minor groove: N1-hydroxylation enhances binding affinity and selectivity to AATT sites. Med Chem Commun. 2015;6:2036–2042.
   Web of Science ®Google Scholar
• Microbiotix Inc. Antifungal compounds. WO2013052263.
   Google Scholar
• Nguyen ST, Kwasny SM, Ding X, et al. Synthesis and antifungal evaluation of head-to-head and head-to-tail bisamidine compounds. Bioorg Med Chem. 2015;23:5789–5798.
   PubMed Web of Science ®Google Scholar
• Syngenta Participations AG. Microbiocidal imidazole derivatives. WO2015162271.
   Google Scholar
• Syngenta Participations AG. Microbiocidal imidazole derivatives. WO2015162268.
   Google Scholar
• Syngenta Participations AG. Microbiocidal imidazole derivatives. WO2015162269.
   Google Scholar
• Zhang L, Sathunuru R, Caridha D, et al. Antimalarial activities of new guanidylimidazole and guanidylimidazoline derivatives. J Med Chem. 2011;54:6634–6646.
   PubMed Web of Science ®Google Scholar
• Spangenberg T, Burrows JN, Kowalczyk P, et al. The open access malaria box: a drug discovery catalyst for neglected diseases. PLoS One. 2013;8:e62906.
   PubMed Web of Science ®Google Scholar
• The United States of America, as represented by the Secretary of Army. Guanidylimidazole and guanidylimidazoline derivatives as antimalarial agents, synthesis of and methods of use thereof. WO2012149097.
   Google Scholar
• Wang X, Dong Y, Cal M, et al. Antiprotozoal selectivity of diimidazoline N-phenylbenzamides. ACS Infect Dis. 2015;1:135–139.
   Web of Science ®Google Scholar
• Nagle PS, McKeever C, Rodriguez F, et al. Unexpected DNA affinity and sequence selectivity through core rigidity in guanidinium-based minor groove binders. J Med Chem. 2014;57:7663–7672.
   PubMed Web of Science ®Google Scholar
• Ríos Martínez CH, Nué Martínez JJ, Ebiloma GU, et al. Lowering the pKa of bisimidazoline lead with halogen atoms results in improved activity and selectivity against Trypanosoma brucei in vitro. Eur J Med Chem. 2015;101:806–817.
   PubMed Web of Science ®Google Scholar
• Ríos Martínez CH, Miller F, Ganeshamoorthy K, et al. A new nonpolar N-hydroxy imidazoline lead compound with improved activity in a murine model of late-stage Trypanosoma brucei infection is not cross-resistant with diamidines. Antimicrob Agents Chemother. 2015;59:890–904.
   PubMed Web of Science ®Google Scholar
• Koperniku A, Papanastasiou I, Foscolos GB, et al. Synthesis and trypanocidal action of new adamantane substituted imidazolines. Med Chem Commun. 2013;4:856–859.
   Web of Science ®Google Scholar
• Navarro M, Marchán E, Maldonaldo A, et al. Anti-trypanosomal activity of platinium-sterol hydrazone imidazoline complexes. Transition Met Chem. 2015;40:707–713.
   Web of Science ®Google Scholar
• Lantheus Medical Imaging Inc. Compositions, methods, and systems for the synthesis and use of imaging agents. WO2013036869.
   Google Scholar